MarketCap
Facebook
X
Telegram
Cytosorbents Corporation Net Income | CTSO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Cytosorbents Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.2 M | -20.7 M | -29.2 M | -32.8 M | -24.6 M | -7.84 M | -19.3 M | -17.2 M | -8.46 M | -11.9 M | -8.13 M | -9.32 M | -4.68 M | -3.66 M | -5.48 M | -2.91 M | -2.74 M | -3.02 M | -3.35 M | -76.7 M | -3.67 M | -1.1 M | -6.01 M | -11.9 M | -15.4 M | -3.07 M | -10.8 M | -1.87 M | -5.26 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.1 M | -76.7 M | -12.4 M |
Quarterly Net Income Cytosorbents Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.42 M | -5.13 M | -3.17 M | 1.95 M | -1.48 M | - | -2.77 M | -4.29 M | -6.09 M | - | -9.19 M | -6.15 M | -7.33 M | - | -12.2 M | -10.9 M | -8.97 M | -9.31 M | -6.41 M | -4.68 M | -4.17 M | -678 K | -840 K | -2.87 M | -3.45 M | -3.95 M | -6.89 M | -3.55 M | -4.88 M | -5.4 M | -3 M | -5.82 M | -2.98 M | -3.15 M | -2.05 M | -1.73 M | -1.52 M | -4.91 M | -2.19 M | -3.01 M | -1.84 M | -2.53 M | -2.85 M | 1.43 M | -4.72 M | -10.5 M | -1.5 M | -1.85 M | -975 K | - | -965 K | -1.41 M | -1.63 M | - | -652 K | -1.05 M | -1.43 M | - | -1.73 M | -1.34 M | -1.21 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | -12.2 M | -3.71 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
-8.3 M | $ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.89 B | $ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-638 K | $ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
4.05 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
11.3 M | $ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-51.1 M | $ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
-14.1 M | - | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
-40.9 M | $ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-517 M | $ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
22.7 M | $ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
93.8 M | $ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
145 M | $ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
22.5 M | $ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
-15.7 M | $ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
410 M | $ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
-34.3 M | $ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
-22 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-55.7 M | - | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
4.8 B | $ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
-54.6 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
147 M | - | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-75 M | $ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
-48.8 M | $ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
-81.7 M | $ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
-42.6 M | $ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
-14.9 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
-48.6 M | $ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
-11.2 M | $ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
-49.2 M | $ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
625 M | $ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
-1.64 M | - | - | $ 4.23 B | USA |